[Antithrombotic activity of RU-891 antiaggregant agent].

Abstract

Antithrombotic action of the novel benzimidazole derivative RU-891 exhibiting antiaggregant activity both in vitro and in vivo has been investigated in comparison to acetylsalicylic acid using the method of thrombosis induced by 50% ferrous chloride solution in rats. RU-891 compound showed dose-dependent antithrombotic activity exceeding that of the reference drug. Taking into account pathogenesis of this experimental thrombosis, it can be suggested that the antithrombotic action ofRU-891 is connected to its antiaggregant activity.

• Authors: A A Spasov, A F Kucheriavenko, M Tian', V A Anisimova
• Journal: Eksperimental'naia i klinicheskaia farmakologiia (Eksp Klin Farmakol) Vol. 76 Issue 6 Pg. 25-6 ( 2013) ISSN: 0869-2092 [Print] Russia (Federation)
• PMID: 24003486 (Publication Type: English Abstract, Journal Article)

Chemical References

• 9-(2-(3,4-dihydroxydiphenyl)-2-oxoethyl)-2,3-dihydroimidazo(1,2-a)benzimidazole
• Benzimidazoles
• Ferrous Compounds
• Fibrinolytic Agents
• Platelet Aggregation Inhibitors
• Aspirin
• ferrous chloride

Topics

• Animals
• Animals, Outbred Strains
• Aspirin (pharmacology)
• Benzimidazoles (pharmacology)
• Blood Platelets (cytology, drug effects)
• Cells, Cultured
• Dose-Response Relationship, Drug
• Ferrous Compounds
• Fibrinolytic Agents (pharmacology)
• Male
• Platelet Aggregation (drug effects)
• Platelet Aggregation Inhibitors (pharmacology)
• Rabbits
• Rats
• Thrombosis (chemically induced, drug therapy)